These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

557 related items for PubMed ID: 17683792

  • 1. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease.
    Fera F, Nicoletti G, Cerasa A, Romeo N, Gallo O, Gioia MC, Arabia G, Pugliese P, Zappia M, Quattrone A.
    Brain Res Bull; 2007 Sep 14; 74(1-3):75-83. PubMed ID: 17683792
    [Abstract] [Full Text] [Related]

  • 2. Brain dopaminergic modulation associated with executive function in Parkinson's disease.
    Farid K, Sibon I, Guehl D, Cuny E, Burbaud P, Allard M.
    Mov Disord; 2009 Oct 15; 24(13):1962-9. PubMed ID: 19672989
    [Abstract] [Full Text] [Related]

  • 3. Prefrontal alterations in Parkinson's disease with levodopa-induced dyskinesia during fMRI motor task.
    Cerasa A, Pugliese P, Messina D, Morelli M, Gioia MC, Salsone M, Novellino F, Nicoletti G, Arabia G, Quattrone A.
    Mov Disord; 2012 Mar 15; 27(3):364-71. PubMed ID: 22076870
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
    Stoffers D, Bosboom JL, Deijen JB, Wolters EC, Berendse HW, Stam CJ.
    Brain; 2007 Jul 15; 130(Pt 7):1847-60. PubMed ID: 17412733
    [Abstract] [Full Text] [Related]

  • 6. Levodopa influences striatal activity but does not affect cortical hyper-activity in Parkinson's disease.
    Martinu K, Degroot C, Madjar C, Strafella AP, Monchi O.
    Eur J Neurosci; 2012 Feb 15; 35(4):572-83. PubMed ID: 22304628
    [Abstract] [Full Text] [Related]

  • 7. [Levodopa and cognitive disorders in Parkinson's disease].
    Leiva-Santana C, Alvarez-Saúco M.
    Rev Neurol; 2012 Feb 15; 43(2):95-100. PubMed ID: 16838257
    [Abstract] [Full Text] [Related]

  • 8. Modulatory effects of levodopa on cognitive control in young but not in older subjects: a pharmacological fMRI study.
    Onur ÖA, Piefke M, Lie CH, Thiel CM, Fink GR.
    J Cogn Neurosci; 2011 Oct 15; 23(10):2797-810. PubMed ID: 21254797
    [Abstract] [Full Text] [Related]

  • 9. Levodopa reinstates connectivity from prefrontal to premotor cortex during externally paced movement in Parkinson's disease.
    Herz DM, Siebner HR, Hulme OJ, Florin E, Christensen MS, Timmermann L.
    Neuroimage; 2014 Apr 15; 90():15-23. PubMed ID: 24269570
    [Abstract] [Full Text] [Related]

  • 10. Levodopa-sensitive, dynamic changes in effective connectivity during simultaneous movements in Parkinson's disease.
    Palmer SJ, Eigenraam L, Hoque T, McCaig RG, Troiano A, McKeown MJ.
    Neuroscience; 2009 Jan 23; 158(2):693-704. PubMed ID: 18722512
    [Abstract] [Full Text] [Related]

  • 11. Dopaminergic effects on cognitive performance in patients with Parkinson's disease.
    Lange KW, Paul GM, Naumann M, Gsell W.
    J Neural Transm Suppl; 1995 Jan 23; 46():423-32. PubMed ID: 8821078
    [Abstract] [Full Text] [Related]

  • 12. Gait analysis in patients with Parkinson's disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function.
    O'Sullivan JD, Said CM, Dillon LC, Hoffman M, Hughes AJ.
    Mov Disord; 1998 Nov 23; 13(6):900-6. PubMed ID: 9827613
    [Abstract] [Full Text] [Related]

  • 13. Dopaminergic influence on disturbed spatial discrimination in Parkinson's disease.
    Shin HW, Kang SY, Sohn YH.
    Mov Disord; 2005 Dec 23; 20(12):1640-3. PubMed ID: 16092109
    [Abstract] [Full Text] [Related]

  • 14. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
    Cools R.
    Neurosci Biobehav Rev; 2006 Dec 23; 30(1):1-23. PubMed ID: 15935475
    [Abstract] [Full Text] [Related]

  • 15. Neural basis for impaired time reproduction in Parkinson's disease: an fMRI study.
    Elsinger CL, Rao SM, Zimbelman JL, Reynolds NC, Blindauer KA, Hoffmann RG.
    J Int Neuropsychol Soc; 2003 Nov 23; 9(7):1088-98. PubMed ID: 14738289
    [Abstract] [Full Text] [Related]

  • 16. A dopamine agonist, pramipexole, and cognitive functions in Parkinson's disease.
    Relja M, Klepac N.
    J Neurol Sci; 2006 Oct 25; 248(1-2):251-4. PubMed ID: 16797593
    [Abstract] [Full Text] [Related]

  • 17. Basal ganglia, dopamine and temporal processing: performance on three timing tasks on and off medication in Parkinson's disease.
    Jones CR, Malone TJ, Dirnberger G, Edwards M, Jahanshahi M.
    Brain Cogn; 2008 Oct 25; 68(1):30-41. PubMed ID: 18378374
    [Abstract] [Full Text] [Related]

  • 18. Spike-timing-related plasticity is preserved in Parkinson's disease and is enhanced by dopamine: evidence from transcranial magnetic stimulation.
    Rodrigues JP, Walters SE, Stell R, Mastaglia FL, Thickbroom GW.
    Neurosci Lett; 2008 Dec 19; 448(1):29-32. PubMed ID: 18952149
    [Abstract] [Full Text] [Related]

  • 19. Semantic activation in Parkinson's disease patients on and off levodopa.
    Angwin AJ, Arnott WL, Copland DA, Haire MP, Murdoch BE, Silburn PA, Chenery HJ.
    Cortex; 2009 Sep 19; 45(8):950-9. PubMed ID: 19356748
    [Abstract] [Full Text] [Related]

  • 20. l-DOPA changes ventral striatum recruitment during motor sequence learning in Parkinson's disease.
    Kwak Y, Müller ML, Bohnen NI, Dayalu P, Seidler RD.
    Behav Brain Res; 2012 Apr 21; 230(1):116-24. PubMed ID: 22343069
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.